<DOC>
	<DOCNO>NCT02949570</DOCNO>
	<brief_summary>To assess efficacy inecalcitol combination imatinib CML patient molecular residual disease imatinib monotherapy .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Inecalcitol Imatinib-Treated Residual Chronic Myeloid Leukaemia : INIM Study</brief_title>
	<detailed_description>To determine : - Duration response - Progression free survival - Proportion responder 2 year discontinuation inecalcitol - Duration response discontinuation inecalcitol imatinib - Bone remodelling effect - Safety inecalcitol combination imatinib - Quality Life</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Men woman age least 18 year time inform consent signature ; Patients sign write informed consent ; ECOG performance status &lt; 2 ; Patients Philadelphia chromosome positive chronic phase CML M BCRABL transcript positivity ( e13a2 e14a2 ) ; Treatment imatinib 2 year ( history treatment interferon tolerate ) ; Patient complete cytogenetic response BCRABL/ABL status 0.1 % International Scale ( IS ) 0.01 % IS BCRABL checkpoint last six month well Molecular Response MR4 ( i.e . BCRABL ratio &lt; 0.01 % IS ) ; Women child bear potential negative pregnancy test prior first dose agree practice effective contraception study ; Fertile men agree practice effective contraception study ; Patients agree comply study requirement agree come clinic require study visit ; Patients agree follow medication restriction study ; Expression unusual BCRABL transcript ( e13a2 e14a2 ) ; Pregnant lactate woman ; Participating another clinical trial investigative drug within 30 day prior study enrolment ( except OPTIM imatinib ) ; Treatment interferon within last 24 month ; Imatinib dose modification within last 3 month ; Prior history haematopoietic stem cell transplantation ; Impaired renal function creatinine clearance &lt; 30 ml/min/1.73m² accord MDRD formula ; Hypercalcemia ( correct albuminemia ) ; History diseases know associated calcium disorder : ongoing hyperparathyroidism , sarcoidosis… . ; Presence history symptomatic kidney stone last 5 year ; Current use drug know influence serum calcium ( thiazide diuretic , teriparatide , calcitonin multivitamin supplement contain &gt; 400 IU vitamin D calcium ) ; Current use digitalis ; Current use drug could influence bioavailability inecalcitol ( magnesiumcontaining antacid , bileresin binder ) ; Patients chronic condition well control , accord investigator , would interfere completion study ; Use experimental drug , therapy vitamin D supplementation within 30 day first inecalcitol administration ; Patients mental deficiency prevent proper understanding trial protocol requirement ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>